Advanced

Vaccines against atherosclerosis.

Nilsson, Jan LU ; Wigren, Maria LU and Shah, Prediman K (2013) In Expert Review of Vaccines 12(3). p.311-321
Abstract
Atherosclerosis is the primary cause of acute myocardial infarction and stroke. It is well established that arterial inflammation in response to accumulation and oxidation of lipoproteins in the vascular wall is the major factor responsible for the development of atherosclerosis. During recent years, it has become apparent that this vascular inflammation is modulated by a complex array of autoimmune responses against modified self-antigens in the atherosclerotic plaque and that both protective and pathogenic immune responses become activated as part of the disease process. Studies of hypercholesterolemia-induced immune activation in mouse models of atherosclerosis have demonstrated that Th1 cells contribute to disease progression while... (More)
Atherosclerosis is the primary cause of acute myocardial infarction and stroke. It is well established that arterial inflammation in response to accumulation and oxidation of lipoproteins in the vascular wall is the major factor responsible for the development of atherosclerosis. During recent years, it has become apparent that this vascular inflammation is modulated by a complex array of autoimmune responses against modified self-antigens in the atherosclerotic plaque and that both protective and pathogenic immune responses become activated as part of the disease process. Studies of hypercholesterolemia-induced immune activation in mouse models of atherosclerosis have demonstrated that Th1 cells contribute to disease progression while regulatory T cells are protective. It has been suggested that antigen presentation of modified self-antigens in the inflammatory environment of atherosclerotic plaques favors generation of antigen-specific Th1 cells over that of regulatory T cells, resulting in a local loss of tolerance. This concept has stimulated the development of plaque-antigen tolerogenic vaccines to dampen plaque inflammation and disease progression. A first generation of atherosclerosis vaccines based on peptides derived from apoB100 and heat shock proteins have demonstrated promising results in animal studies and are now approaching clinical testing. (Less)
Please use this url to cite or link to this publication:
author
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Expert Review of Vaccines
volume
12
issue
3
pages
311 - 321
publisher
Future Drugs Ltd
external identifiers
  • wos:000316255700012
  • pmid:23496670
  • scopus:84875147210
  • pmid:23496670
ISSN
1744-8395
DOI
10.1586/erv.13.4
language
English
LU publication?
yes
id
6f7919a4-0f92-48b1-bd49-e419d1d6d807 (old id 3628146)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/23496670?dopt=Abstract
date added to LUP
2016-04-01 09:53:25
date last changed
2020-01-05 03:32:52
@article{6f7919a4-0f92-48b1-bd49-e419d1d6d807,
  abstract     = {Atherosclerosis is the primary cause of acute myocardial infarction and stroke. It is well established that arterial inflammation in response to accumulation and oxidation of lipoproteins in the vascular wall is the major factor responsible for the development of atherosclerosis. During recent years, it has become apparent that this vascular inflammation is modulated by a complex array of autoimmune responses against modified self-antigens in the atherosclerotic plaque and that both protective and pathogenic immune responses become activated as part of the disease process. Studies of hypercholesterolemia-induced immune activation in mouse models of atherosclerosis have demonstrated that Th1 cells contribute to disease progression while regulatory T cells are protective. It has been suggested that antigen presentation of modified self-antigens in the inflammatory environment of atherosclerotic plaques favors generation of antigen-specific Th1 cells over that of regulatory T cells, resulting in a local loss of tolerance. This concept has stimulated the development of plaque-antigen tolerogenic vaccines to dampen plaque inflammation and disease progression. A first generation of atherosclerosis vaccines based on peptides derived from apoB100 and heat shock proteins have demonstrated promising results in animal studies and are now approaching clinical testing.},
  author       = {Nilsson, Jan and Wigren, Maria and Shah, Prediman K},
  issn         = {1744-8395},
  language     = {eng},
  number       = {3},
  pages        = {311--321},
  publisher    = {Future Drugs Ltd},
  series       = {Expert Review of Vaccines},
  title        = {Vaccines against atherosclerosis.},
  url          = {http://dx.doi.org/10.1586/erv.13.4},
  doi          = {10.1586/erv.13.4},
  volume       = {12},
  year         = {2013},
}